# Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

> **NCT00408772** · PHASE2 · WITHDRAWN · sponsor: **University of California, Davis**

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** oxaliplatin
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** radiofrequency ablation

## Key facts

- **NCT ID:** NCT00408772
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408772, "Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00408772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*